-
. The successful candidate must possess an MD or MD/PhD (or equivalent), be Board Certified or Board eligible in Clinical Pathology at the time of appointment and must have or be eligible for a medical license in
-
sequencing, proteomics, and behavioral testing to uncover the mechanisms driving the pathogenesis and neuropathology of AD and TBI-induced AD-like neuropathology. Candidates should possess a PhD and/or MD in
-
networking opportunities, training sessions, mentoring and funding possibilities to fuel your research endeavors. Qualifications: PhD, MD, MD/PhD degrees and postdoctoral research experience; Strong
-
networking opportunities, training sessions, mentoring and funding possibilities to fuel your research endeavors. Qualifications: MD, MD/PhD or PhD and postdoctoral research experience Strong publication
-
-rate background in academic training—specifically, a PhD in relevant disciplines, experience in studying and/or working at first-rate teaching and research institutions, and knowledge of the latest
-
teaching and learning formats including lectures, seminars, online courses, group discussions, and a term project. Applicants must have a PhD degree in relevant fields. Applicant should have proven teaching
-
Postdoc in CRISPR Meta-Analytics and AI for Therapeutic Target Discovery and Priotisation (OT Grant)
presenting advances and results to Open Targets meetings and Integration days. Job requirements Essential requirements Hands-on experience in data science, preferably life sciences or medicine. A PhD degree
-
years of research experience or PhD in molecular biology, biochemistry, or structural biology. Autonomy in cell culture of mammalian cells. Experience in standard wet lab techniques such as cloning
-
, PhD, VMD, or DDS) in area directly related to field of research specialization. Experience and Skills: Acquires thorough technical and theoretical knowledge of research project and objectives during one
-
in vitro. Clive Svendsen, PhD, has significant experience in studying these diseases over the last twenty years and is merging his experience with the use of leading-edge technologies, such as